DuPont announced it exercised its option to acquire full ownership of OxyMem Limited, an Irish company that develops and produces Membrane Aerated Biofilm Reactor (MABR) technology for the treatment and purification of municipal and industrial wastewater.
OxyMem has more than 60 employees and one production site located in Athlone, Ireland. The transaction will close before Dec. 31, 2019.
OxyMem was founded in 2013, based on a technology spin-out from the University College Dublin.
The company is engaged in the development, manufacturing, and sales of MABR units using patented technology to treat wastewater. DuPont already owns 31 percent of the company and has exercised its option to acquire all outstanding shares of OxyMem for 100 percent ownership.
“MABR is a new technology that offers unique and differentiated performance for secondary wastewater treatment over existing technologies,” said HP Nanda, global vice president and general manager, DuPont Water Solutions. “Wastewater is a fast-growing global market driven by industrial expansion, challenging water conditions and tightening regulations. Together with the MEMCOR MBR product DuPont is acquiring, this additional emerging technology provides more solutions for customers looking to reduce footprint and energy requirements for secondary wastewater treatment and enhances the performance of systems using other traditional water purification, reuse and recovery technologies.”
DuPont offers water purification and separation technology including ultrafiltration, reverse osmosis and ion exchange resins.
Each of the acquisitions announced this year supports our strategy to drive growth and innovation through access to new manufacturing capabilities, geographies and technologies, a release stated.
DuPont is continuing to make “bolt-on” acquisitions as it continues to shape its portfolio of businesses. This week, it was announced that the company will merge its Nutrition and Industrial Biosciences business with IFF in a $26 billion deal that gives DuPont shareholders a controlling interest in the combined companies.